Carolwood Marketing EFAin EU as Diabetes Treatment

Carolwood Marketing EFAin EU as Diabetes Treatment

GREENVILLE, Pa.--CarolwoodCorp. is marketing its essential fatty acid (EFA) supplement, Entrox, as atreatment for Type II diabetes and for controlling risk factors for the disease. In addition, the company is sponsoring a clinical study on the effectiveness of Entrox in improving long-term blood sugar levelsin diabetics; the placebo-controlled, double-blind study will be conducted at the Medical University of Bonn, Germany, and should finish by October 2001. Details on Entrox are available atwww.msm.com.